Cargando…
Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Androgen deprivation therapy (ADT) with gonadotropin-releasing hormone (GnRH) agonists and antagonists is the mainstay of advanced prostate cancer treatment. Both drug classes decrease levels of luteinizing hormone and follicle-stimulating hormones (FSH), thereby lowering testosterone to castrate le...
Autores principales: | Freedland, Stephen J, Abrahamsson, Per-Anders |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831824/ https://www.ncbi.nlm.nih.gov/pubmed/32655041 http://dx.doi.org/10.4103/aja.aja_22_20 |
Ejemplares similares
-
Comparison of GnRH Agonist, GnRH Antagonist, and GnRH Antagonist Mild Protocol of Controlled Ovarian Hyperstimulation in Good Prognosis Patients
por: Stimpfel, Martin, et al.
Publicado: (2015) -
Combination GnRH antagonists for endometriosis: Balancing efficacy with side effects
por: Whitaker, L.H.R., et al.
Publicado: (2022) -
A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer
por: Miki, Kenta, et al.
Publicado: (2016) -
GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology
por: Cota, Ana Marcia M, et al.
Publicado: (2012) -
Comparison of long GnRH agonist versus GnRH antagonist protocol in poor responders
por: Şahin, Sadık, et al.
Publicado: (2014)